Dr. David Dulaney, MD
Gastroenterology (Gastroenterology Physician)
At a glance
- In the NPI registry since
- 2015
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
VA license 0101261325 -
General Practice Physician
VA license 0101261325 -
Internal Medicine Physician
VA license 0101261325
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 6 companies reported 73 payments worth $84,735 in total to this clinician.
| Genzyme Corporation | $25,900 |
|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $24,786 |
| Regeneron Healthcare Solutions, Inc. | $18,292 |
| Lilly USA, LLC | $15,639 |
| Pfizer Inc. | $80.81 |
| AbbVie Inc. | $37.11 |
| Compensation for services other than consulting (speaking, faculty) | $71,910 |
|---|---|
| Travel and Lodging | $11,182 |
| Food and Beverage | $1,643 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation May 8, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $8,725 |
| Genzyme Corporation Jun 18, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $8,725 |
| Regeneron Healthcare Solutions, Inc. Jan 28, 2025 | Compensation for services other than consulting (speaking, faculty) | $8,725 |
| Takeda Pharmaceuticals U.S.A., Inc. Jul 21, 2025 | Compensation for services other than consulting (speaking, faculty) ENTYVIO · INTERNAL MEDICINE | $7,142 |
| Takeda Pharmaceuticals U.S.A., Inc. Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty) ENTYVIO · INTERNAL MEDICINE | $7,142 |
| Lilly USA, LLC Feb 10, 2025 | Compensation for services other than consulting (speaking, faculty) OMVOH · Immunology | $5,625 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 4, 2025 | Compensation for services other than consulting (speaking, faculty) ENTYVIO · INTERNAL MEDICINE | $5,279 |
| Genzyme Corporation Apr 17, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $3,839 |
| Regeneron Healthcare Solutions, Inc. Aug 8, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $3,141 |
| Regeneron Healthcare Solutions, Inc. Jan 30, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $3,141 |
All 49 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. Dec 3, 2025 | Travel and Lodging travel to CEDAR RAPIDS, IA · in-kind | $497 |
| Takeda Pharmaceuticals U.S.A., Inc. Dec 3, 2025 | Travel and Lodging travel to CEDAR RAPIDS, IA · in-kind | $144 |
| Takeda Pharmaceuticals U.S.A., Inc. Dec 3, 2025 | Travel and Lodging travel to CEDAR RAPIDS, IA · in-kind | $135 |
| Lilly USA, LLC Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty) OMVOH · Immunology | $1,250 |
| Lilly USA, LLC Sep 24, 2025 | Compensation for services other than consulting (speaking, faculty) OMVOH · Immunology | $1,250 |
| Lilly USA, LLC Sep 17, 2025 | Compensation for services other than consulting (speaking, faculty) OMVOH · Immunology | $2,500 |
| Lilly USA, LLC Sep 17, 2025 | Compensation for services other than consulting (speaking, faculty) OMVOH · Immunology | $1,575 |
| Lilly USA, LLC Sep 15, 2025 | Travel and Lodging travel to AUSTIN, TX · in-kind | $628 |
| Lilly USA, LLC Aug 28, 2025 | Compensation for services other than consulting (speaking, faculty) OMVOH · Immunology | $1,875 |
| Regeneron Healthcare Solutions, Inc. Aug 8, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $3,141 |
| Takeda Pharmaceuticals U.S.A., Inc. Jul 21, 2025 | Compensation for services other than consulting (speaking, faculty) ENTYVIO · INTERNAL MEDICINE | $7,142 |
| Takeda Pharmaceuticals U.S.A., Inc. Jul 21, 2025 | Travel and Lodging ENTYVIO · INTERNAL MEDICINE · travel to LUBBOCK, TX · in-kind | $61.95 |
| Takeda Pharmaceuticals U.S.A., Inc. Jul 21, 2025 | Travel and Lodging ENTYVIO · INTERNAL MEDICINE · travel to LUBBOCK, TX · in-kind | $12.18 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 25, 2025 | Travel and Lodging ENTYVIO · INTERNAL MEDICINE · travel to LUBBOCK, TX · in-kind | $983 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 25, 2025 | Travel and Lodging ENTYVIO · INTERNAL MEDICINE · travel to LUBBOCK, TX · in-kind | $506 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 25, 2025 | Travel and Lodging ENTYVIO · INTERNAL MEDICINE · travel to LUBBOCK, TX · in-kind | $212 |
| Genzyme Corporation Jun 18, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $8,725 |
| Genzyme Corporation Jun 18, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Anchorage, AK · in-kind | $1,240 |
| Genzyme Corporation Jun 18, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Anchorage, AK · in-kind | $548 |
| Genzyme Corporation Jun 18, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Anchorage, AK · in-kind | $413 |
| Genzyme Corporation Jun 18, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Anchorage, AK | $70.56 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 4, 2025 | Compensation for services other than consulting (speaking, faculty) ENTYVIO · INTERNAL MEDICINE | $5,279 |
| Takeda Pharmaceuticals U.S.A., Inc. May 15, 2025 | Travel and Lodging ENTYVIO · INTERNAL MEDICINE · travel to BRYAN, TX · in-kind | $1,029 |
| Genzyme Corporation May 8, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $8,725 |
| Genzyme Corporation May 8, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Vacaville, CA · in-kind | $665 |
| Genzyme Corporation May 8, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Vacaville, CA · in-kind | $595 |
| Genzyme Corporation May 8, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Vacaville, CA · in-kind | $338 |
| Genzyme Corporation May 8, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Vacaville, CA | $88.67 |
| Genzyme Corporation Apr 17, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $3,839 |
| Genzyme Corporation Apr 17, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to San Antonio, TX | $22.54 |
| Regeneron Healthcare Solutions, Inc. Apr 4, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to ALBUQUERQUE, NM · in-kind | $79.44 |
| Regeneron Healthcare Solutions, Inc. Apr 4, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to ALBUQUERQUE, NM · in-kind | $11.83 |
| Regeneron Healthcare Solutions, Inc. Mar 21, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,978 |
| Takeda Pharmaceuticals U.S.A., Inc. Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty) ENTYVIO · INTERNAL MEDICINE | $7,142 |
| Takeda Pharmaceuticals U.S.A., Inc. Mar 20, 2025 | Travel and Lodging ENTYVIO · INTERNAL MEDICINE · travel to FORT WORTH, TX · in-kind | $45.71 |
| Takeda Pharmaceuticals U.S.A., Inc. Mar 20, 2025 | Travel and Lodging ENTYVIO · INTERNAL MEDICINE · travel to FORT WORTH, TX · in-kind | $19.56 |
| Takeda Pharmaceuticals U.S.A., Inc. Mar 20, 2025 | Travel and Lodging ENTYVIO · INTERNAL MEDICINE · travel to FORT WORTH, TX · in-kind | $11.62 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 26, 2025 | Travel and Lodging ENTYVIO · INTERNAL MEDICINE · travel to FORT WORTH, TX · in-kind | $566 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 26, 2025 | Travel and Lodging ENTYVIO · INTERNAL MEDICINE · travel to FORT WORTH, TX · in-kind | $376 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 26, 2025 | Travel and Lodging ENTYVIO · INTERNAL MEDICINE · travel to FORT WORTH, TX · in-kind | $192 |
| Lilly USA, LLC Feb 10, 2025 | Compensation for services other than consulting (speaking, faculty) OMVOH · Immunology | $5,625 |
| Lilly USA, LLC Jan 31, 2025 | Travel and Lodging travel to CHARLOTTE, NC · in-kind | $496 |
| Lilly USA, LLC Jan 31, 2025 | Travel and Lodging travel to CHARLOTTE, TX · in-kind | $145 |
| Lilly USA, LLC Jan 31, 2025 | Travel and Lodging travel to CHARLOTTE, TX · in-kind | $145 |
| Regeneron Healthcare Solutions, Inc. Jan 30, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $3,141 |
| Regeneron Healthcare Solutions, Inc. Jan 29, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to ALBUQUERQUE, NM · in-kind | $166 |
| Regeneron Healthcare Solutions, Inc. Jan 28, 2025 | Compensation for services other than consulting (speaking, faculty) | $8,725 |
| Regeneron Healthcare Solutions, Inc. Jan 28, 2025 | Travel and Lodging travel to ALBUQUERQUE, NM · in-kind | $497 |
| Regeneron Healthcare Solutions, Inc. Jan 24, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to ALBUQUERQUE, NM · in-kind | $242 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $27,967 in research payments for these studies, mostly to the institutions running them.
- A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06693531
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.